Bioventus (BVS) vs. Its Rivals Critical Survey

Bioventus (NASDAQ:BVS) is one of 28 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its rivals? We will compare Bioventus to related businesses based on the strength of its earnings, dividends, profitability, risk, valuation, analyst recommendations and institutional ownership.

Volatility and Risk

Bioventus has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Bioventus’ rivals have a beta of 1.76, meaning that their average share price is 76% more volatile than the S&P 500.

Earnings & Valuation

This table compares Bioventus and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Bioventus	$563.83 million	-$33.54 million	68.92
Bioventus Competitors	$57.98 million	-$32.15 million	4.18

Bioventus has higher revenue, but lower earnings than its rivals. Bioventus is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Bioventus and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	1.39%	26.38%	7.27%
Bioventus Competitors	-672.41%	-133.75%	-59.01%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Bioventus and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0	1	0	1	3.00
Bioventus Competitors	77	76	156	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 51.09%. Given Bioventus’ rivals higher possible upside, analysts clearly believe Bioventus has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

62.9% of Bioventus shares are held by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 33.0% of Bioventus shares are held by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Bioventus beats its rivals on 9 of the 13 factors compared.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.